Index RUT P/E - EPS (ttm) -0.38 Insider Own 0.80% Shs Outstand 164.65M Perf Week 2.03%
Market Cap 2.82B Forward P/E 13.57 EPS next Y 1.26 Insider Trans -7.57% Shs Float 163.89M Perf Month -5.54%
Income -61.29M PEG - EPS next Q 0.05 Inst Own 96.71% Short Float 6.81% Perf Quarter -32.58%
Sales 726.44M P/S 3.88 EPS this Y 273.60% Inst Trans 0.91% Short Ratio 6.16 Perf Half Y -25.61%
Book/sh 2.62 P/B 6.50 EPS next Y 95.66% ROA -9.17% Short Interest 11.16M Perf Year -19.58%
Cash/sh 2.66 P/C 6.42 EPS next 5Y - ROE -14.73% 52W Range 16.16 - 33.99 Perf YTD -45.54%
Dividend Est. - P/FCF 169.17 EPS past 5Y 28.03% ROI -12.78% 52W High -49.84% Beta 0.43
Dividend TTM - Quick Ratio 2.28 Sales past 5Y 27.73% Gross Margin 94.27% 52W Low 5.51% ATR (14) 0.62
Dividend Ex-Date - Current Ratio 2.42 EPS Y/Y TTM 71.78% Oper. Margin -10.10% RSI (14) 41.02 Volatility 3.86% 3.06%
Employees 598 Debt/Eq 0.13 Sales Y/Y TTM 40.45% Profit Margin -8.44% Recom 1.71 Target Price 28.79
Option/Short Yes / Yes LT Debt/Eq 0.11 EPS Q/Q 206.75% Payout - Rel Volume 0.64 Prev Close 17.08
Sales Surprise 3.24% EPS Surprise -3.08% Sales Q/Q 69.27% Earnings May 08 AMC Avg Volume 1.81M Price 17.05
SMA20 -0.46% SMA50 -12.26% SMA200 -29.63% Trades
Volume 1,159,977 Change -0.18%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-12-24 Reiterated Needham
Buy
$36 → $32
Mar-12-24 Downgrade Mizuho
Buy → Neutral
$39 → $25
Jan-30-24 Initiated Robert W. Baird
Outperform
$40
Jan-24-24 Upgrade Needham
Hold → Buy
$37
Dec-19-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$31 → $40
Dec-14-23 Downgrade Deutsche Bank
Buy → Hold
$25
Dec-13-23 Initiated Citigroup
Buy
$38
Dec-12-23 Initiated Deutsche Bank
Buy
$25
Nov-06-23 Upgrade Mizuho
Neutral → Buy
$20 → $35
Oct-17-23 Initiated UBS
Buy
$33
Oct-10-23 Upgrade JP Morgan
Neutral → Overweight
$29 → $32
Jan-03-23 Upgrade Guggenheim
Neutral → Buy
$22
Nov-04-22 Downgrade Goldman
Neutral → Sell
$15 → $12
Nov-01-22 Initiated Loop Capital
Hold
$17
Aug-08-22 Downgrade Citigroup
Buy → Neutral
$19 → $15
Aug-05-22 Downgrade Citigroup
Buy → Neutral
$19 → $15
Jun-21-22 Downgrade Jefferies
Buy → Underperform
$25 → $10
Jun-16-22 Upgrade Jefferies
Hold → Buy
$25
Mar-16-22 Upgrade Canaccord Genuity
Hold → Buy
$30 → $31
Feb-09-22 Upgrade H.C. Wainwright
Neutral → Buy
$36
Show Previous Ratings
May-04-24 02:27AM
May-01-24 10:01AM
Apr-30-24 12:17PM
Apr-29-24 04:16PM
Apr-24-24 04:05PM
09:04AM
Loading…
Apr-22-24 09:04AM
Apr-20-24 09:15AM
Apr-19-24 04:05PM
Apr-17-24 04:05PM
Apr-11-24 02:10PM
Apr-10-24 01:28AM
Apr-02-24 04:05PM
Apr-01-24 04:05PM
Mar-28-24 11:30AM
02:00AM
01:31PM
Loading…
Mar-20-24 01:31PM
Mar-15-24 04:05PM
Mar-14-24 06:49PM
Mar-13-24 04:05PM
Mar-12-24 04:08PM
(Investor's Business Daily) -17.20%
03:05PM
11:06AM
09:30AM
07:43AM
Mar-11-24 04:46PM
04:13PM
04:05PM
Feb-29-24 09:05AM
08:44AM
Feb-28-24 04:05PM
(Investor's Business Daily) -9.92%
09:12AM
Loading…
09:12AM
Feb-27-24 05:20PM
04:56PM
04:27PM
(Associated Press Finance)
04:05PM
Feb-22-24 08:16PM
Feb-21-24 04:05PM
Feb-20-24 10:00AM
Feb-13-24 04:05PM
Feb-08-24 01:15PM
Jan-30-24 08:48PM
05:00PM
Jan-26-24 05:31PM
Jan-25-24 08:42AM
Jan-19-24 04:05PM
Jan-18-24 04:05PM
Jan-12-24 05:02PM
Dec-21-23 04:05PM
Dec-18-23 04:05PM
Dec-13-23 09:24PM
04:14PM
(Investor's Business Daily)
01:41PM
Nov-30-23 09:05AM
Nov-27-23 09:05AM
Nov-21-23 11:03PM
05:00PM
Nov-17-23 09:40AM
Nov-16-23 08:42AM
Nov-14-23 04:12PM
Nov-08-23 05:24PM
Nov-04-23 01:10PM
Nov-02-23 06:51PM
04:37PM
(Associated Press Finance)
04:05PM
Oct-31-23 04:05PM
Oct-26-23 10:02AM
Oct-23-23 09:05AM
Oct-19-23 04:05PM
Oct-18-23 05:00PM
Oct-10-23 10:49AM
09:32AM
Oct-07-23 05:01AM
Sep-30-23 10:30AM
Sep-22-23 06:23PM
Sep-19-23 04:05PM
Aug-30-23 04:05PM
Aug-28-23 06:00PM
Aug-22-23 08:30AM
Aug-19-23 10:44AM
Aug-14-23 04:05PM
Aug-04-23 12:36PM
Aug-02-23 04:26PM
04:05PM
Aug-01-23 07:30PM
Jul-25-23 11:21AM
Jul-24-23 04:05PM
Jul-21-23 09:40AM
Jul-19-23 04:04PM
Jul-15-23 08:19AM
Jul-14-23 04:04PM
(Investor's Business Daily) +24.73%
11:41AM
Jul-13-23 07:11PM
04:05PM
Jun-26-23 05:00PM
Jun-13-23 04:05PM
Jun-12-23 01:24PM
Jun-08-23 11:10AM
Jun-07-23 11:30AM
05:58AM
Jun-01-23 09:04AM
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DAVIS STEPHEN CEO May 02 '24 Sale 16.94 11,427 193,573 155,231 May 03 06:00 PM Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER May 02 '24 Sale 16.94 3,503 59,341 32,053 May 03 06:00 PM Teehan Brendan EVP, COO, HEAD OF COMMERCIAL May 02 '24 Sale 16.94 3,477 58,900 42,133 May 03 06:00 PM Kihara James PRINCIPAL ACCOUNTING OFFICER May 02 '24 Sale 16.94 1,326 22,462 14,370 May 03 06:00 PM DAVIS STEPHEN CEO Apr 08 '24 Sale 17.87 26,574 474,877 144,267 Apr 09 06:00 PM Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Apr 08 '24 Sale 17.87 2,716 48,535 28,742 Apr 09 06:00 PM Teehan Brendan EVP, COO, HEAD OF COMMERCIAL Apr 08 '24 Sale 17.87 2,568 45,890 38,796 Apr 09 06:00 PM Kihara James PRINCIPAL ACCOUNTING OFFICER Apr 08 '24 Sale 17.87 1,790 31,987 13,100 Apr 09 06:00 PM DAVIS STEPHEN CEO Mar 27 '24 Sale 17.90 17,714 317,081 118,842 Mar 27 07:58 PM Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Mar 27 '24 Sale 17.90 5,434 97,269 26,183 Mar 27 07:57 PM Teehan Brendan EVP, COO, HEAD OF COMMERCIAL Mar 27 '24 Sale 17.90 5,140 92,006 36,340 Mar 27 08:00 PM DAVIS STEPHEN CEO Feb 26 '24 Sale 24.67 5,577 137,585 101,890 Feb 27 06:02 PM Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Feb 26 '24 Sale 24.67 772 19,045 21,067 Feb 27 06:13 PM Teehan Brendan EVP, COO, HEAD OF COMMERCIAL Feb 26 '24 Sale 24.67 624 15,394 31,432 Feb 27 06:10 PM Kihara James PRINCIPAL ACCOUNTING OFFICER Feb 26 '24 Sale 24.67 474 11,694 11,391 Feb 27 06:07 PM DAVIS STEPHEN CEO Jan 08 '24 Sale 29.96 3,732 111,811 96,521 Jan 09 06:00 PM Teehan Brendan EVP, COO, Head of Commercial Jan 08 '24 Sale 29.96 731 21,901 30,949 Jan 09 06:00 PM KIM AUSTIN D. EVP,General Counsel, Secretary Jan 08 '24 Sale 29.96 590 17,676 46,901 Jan 09 06:00 PM Kihara James Principal Accounting Officer Dec 15 '23 Sale 28.30 2,000 56,600 11,025 Dec 15 07:37 PM Schneyer Mark C. EVP, Chief Financial Officer Nov 20 '23 Sale 22.64 5,108 115,645 20,486 Nov 21 06:00 PM Teehan Brendan EVP, COO, Head of Commercial Nov 20 '23 Sale 22.64 4,960 112,294 30,393 Nov 21 06:00 PM Kihara James Principal Accounting Officer Nov 20 '23 Sale 22.64 1,985 44,940 13,025 Nov 21 06:00 PM DAVIS STEPHEN CEO Oct 06 '23 Sale 21.96 51,563 1,132,323 89,131 Oct 06 09:59 PM KIM AUSTIN D. EVP,General Counsel, Secretary Oct 06 '23 Sale 21.96 16,369 359,463 45,857 Oct 06 10:00 PM Kihara James Principal Accounting Officer Sep 15 '23 Sale 25.88 2,000 51,760 10,778 Sep 19 06:31 PM Schneyer Mark C. EVP, Chief Financial Officer Aug 21 '23 Sale 29.00 10,000 289,970 15,682 Aug 23 07:31 PM DAVIS STEPHEN CEO Jul 14 '23 Option Exercise 20.77 100,000 2,077,000 136,695 Jul 18 06:00 PM DAVIS STEPHEN CEO Jul 14 '23 Sale 30.04 100,000 3,004,350 36,695 Jul 18 06:00 PM DAVIS STEPHEN CEO Jul 12 '23 Sale 25.05 55,104 1,380,449 36,695 Jul 13 08:27 PM DAVIS STEPHEN CEO Jul 11 '23 Sale 25.00 16,498 412,450 91,799 Jul 13 08:27 PM Kihara James Principal Accounting Officer Jun 15 '23 Sale 24.15 2,000 48,300 9,144 Jun 16 04:38 PM Brege Laura Director Jun 12 '23 Sale 24.87 4,500 111,906 13,502 Jun 14 05:14 PM Schneyer Mark C. EVP, Chief Financial Officer Jun 08 '23 Option Exercise 0.00 1,893 0 23,798 Jun 12 08:48 PM Schneyer Mark C. EVP, Chief Financial Officer Jun 08 '23 Sale 25.02 974 24,369 22,824 Jun 12 08:48 PM BAKER BROS. ADVISORS LP Director May 24 '23 Buy 25.48 553,263 14,096,825 39,317,673 May 24 05:09 PM BAKER BROS. ADVISORS LP Director May 23 '23 Option Exercise 17.01 25,000 425,250 38,620,261 May 24 05:09 PM BAKER BROS. ADVISORS LP Director May 23 '23 Buy 25.41 209,053 5,312,458 38,811,515 May 24 05:09 PM BAKER BROS. ADVISORS LP Director May 22 '23 Buy 24.57 134,206 3,297,815 38,607,761 May 24 05:09 PM Schneyer Mark C. EVP, Chief Financial Officer May 17 '23 Sale 22.50 15,310 344,475 21,905 May 19 06:48 PM Teehan Brendan EVP, COO, Head of Commercial May 17 '23 Sale 22.50 14,869 334,552 24,356 May 19 06:43 PM Kihara James Principal Accounting Officer May 17 '23 Sale 22.50 5,947 133,808 11,144 May 19 06:54 PM
Index RUT P/E 35.08 EPS (ttm) 0.78 Insider Own 2.87% Shs Outstand 46.48M Perf Week 3.34%
Market Cap 1.27B Forward P/E 7.68 EPS next Y 3.54 Insider Trans -8.20% Shs Float 45.19M Perf Month -4.19%
Income 41.95M PEG 3.37 EPS next Q 0.62 Inst Own 106.30% Short Float 7.63% Perf Quarter -10.32%
Sales 674.98M P/S 1.88 EPS this Y -1.26% Inst Trans 2.37% Short Ratio 7.09 Perf Half Y -3.89%
Book/sh 18.72 P/B 1.45 EPS next Y 27.67% ROA 2.58% Short Interest 3.45M Perf Year -36.90%
Cash/sh 5.99 P/C 4.54 EPS next 5Y 10.40% ROE 5.10% 52W Range 25.33 - 45.45 Perf YTD -19.35%
Dividend Est. - P/FCF 9.07 EPS past 5Y - ROI 2.92% 52W High -40.13% Beta 0.84
Dividend TTM - Quick Ratio 4.17 Sales past 5Y 15.46% Gross Margin 64.15% 52W Low 7.42% ATR (14) 0.88
Dividend Ex-Date - Current Ratio 5.24 EPS Y/Y TTM 155.39% Oper. Margin 12.94% RSI (14) 49.36 Volatility 2.94% 3.14%
Employees 712 Debt/Eq 0.67 Sales Y/Y TTM 1.22% Profit Margin 6.22% Recom 1.20 Target Price 45.30
Option/Short Yes / Yes LT Debt/Eq 0.65 EPS Q/Q 316.94% Payout 0.00% Rel Volume 0.51 Prev Close 27.32
Sales Surprise 0.35% EPS Surprise 0.76% Sales Q/Q 5.40% Earnings May 07 AMC Avg Volume 485.88K Price 27.21
SMA20 1.36% SMA50 -4.47% SMA200 -12.57% Trades
Volume 247,306 Change -0.40%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-07-24 Resumed JP Morgan
Overweight
$80 → $45
Dec-20-23 Initiated Raymond James
Outperform
$42
Aug-03-23 Upgrade TD Cowen
Market Perform → Outperform
$50
Jan-31-23 Resumed Wedbush
Outperform
$88 → $60
Oct-21-22 Resumed Jefferies
Buy
$66
Jan-03-22 Resumed JP Morgan
Overweight
$75 → $83
Jul-26-21 Upgrade JP Morgan
Neutral → Overweight
$75
Apr-21-21 Resumed JP Morgan
Neutral
$70
Apr-09-21 Initiated Berenberg
Buy
$93
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$86
Feb-11-21 Downgrade Northland Capital
Outperform → Market Perform
$72 → $75
Jan-21-21 Downgrade SVB Leerink
Outperform → Mkt Perform
$75
Sep-21-20 Upgrade Northland Capital
Market Perform → Outperform
$58 → $67
Jul-06-20 Reiterated Needham
Buy
$52 → $64
May-27-20 Initiated Guggenheim
Neutral
Apr-07-20 Initiated Northland Capital
Outperform
$50
Mar-20-20 Upgrade SVB Leerink
Mkt Perform → Outperform
$44
Feb-24-20 Reiterated H.C. Wainwright
Buy
$60 → $63
Jan-24-20 Initiated SunTrust
Buy
Jan-23-20 Initiated SunTrust
Buy
Show Previous Ratings
Apr-30-24 08:00AM
Apr-04-24 11:33AM
Apr-02-24 08:00AM
Mar-14-24 08:23AM
Mar-13-24 07:00AM
11:55PM
Loading…
Mar-08-24 11:55PM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
Mar-01-24 08:38AM
06:05AM
12:28AM
(Thomson Reuters StreetEvents)
Feb-29-24 10:00AM
09:15AM
08:32AM
08:26AM
(Associated Press Finance)
08:00AM
Loading…
08:00AM
Feb-22-24 08:00AM
Feb-15-24 08:36AM
Feb-07-24 08:00AM
Feb-01-24 10:45AM
Jan-05-24 12:21PM
Jan-04-24 05:00PM
Jan-03-24 08:00AM
Dec-21-23 07:30AM
Dec-06-23 11:13AM
Nov-13-23 10:10AM
Nov-10-23 07:30AM
Nov-07-23 08:00AM
Nov-04-23 10:28AM
Nov-02-23 12:34PM
10:00AM
Loading…
10:00AM
08:23AM
(Associated Press Finance)
08:00AM
Oct-26-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-02-23 08:00AM
Sep-27-23 12:07PM
11:50AM
Sep-26-23 04:30PM
Sep-06-23 08:00AM
Aug-03-23 10:03AM
Aug-02-23 12:45PM
08:11AM
08:00AM
Jul-28-23 02:56PM
Jul-26-23 08:00AM
Jun-21-23 08:00PM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-09-23 08:00AM
May-03-23 11:42PM
(Thomson Reuters StreetEvents) -7.17%
05:25PM
03:11PM
08:11AM
08:00AM
Apr-26-23 08:00PM
08:00AM
Apr-20-23 09:20AM
08:00AM
Apr-19-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 11:30AM
Mar-29-23 08:00AM
Mar-27-23 08:00AM
Mar-24-23 08:50AM
Mar-22-23 08:00AM
Mar-09-23 09:17AM
Mar-08-23 08:00AM
Feb-28-23 11:39PM
(Thomson Reuters StreetEvents)
08:00AM
Feb-23-23 08:00AM
Feb-21-23 08:00AM
Jan-05-23 04:30PM
Jan-04-23 08:00AM
Dec-20-22 10:06AM
Dec-13-22 08:00AM
Nov-18-22 01:38PM
Nov-17-22 08:05AM
Nov-14-22 08:00AM
Nov-09-22 05:14AM
Nov-08-22 08:00AM
Nov-04-22 10:54AM
Nov-03-22 09:15AM
08:00AM
Nov-01-22 10:01AM
Oct-27-22 10:02AM
Oct-20-22 08:00AM
Oct-15-22 08:34AM
Oct-13-22 08:00AM
Oct-07-22 02:10PM
(Investor's Business Daily)
Sep-27-22 08:00AM
Sep-21-22 06:04PM
10:08AM
08:00AM
Sep-20-22 08:00AM
Sep-13-22 08:00AM
Sep-08-22 10:42AM
Sep-07-22 11:07AM
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PACE GARY W Director Mar 08 '24 Sale 30.60 90,000 2,754,000 22,127 Mar 08 05:33 PM PACE GARY W Director Mar 07 '24 Sale 30.81 28,257 870,598 112,127 Mar 08 05:33 PM PACE GARY W Director Mar 06 '24 Sale 29.67 1,066 31,628 140,384 Mar 08 05:33 PM WINSTON ROY Chief Medical Officer Aug 02 '23 Sale 34.88 509 17,751 52,440 Aug 04 04:47 PM Riker Lauren Bullaro Senior Vice President, Finance Jul 05 '23 Sale 38.91 643 25,019 22,687 Jul 07 08:04 PM Riker Lauren Bullaro Senior Vice President, Finance Jun 14 '23 Sale 38.42 6,366 244,606 22,687 Jun 16 05:39 PM Williams Kristen Marie Chief Administrative Officer Jun 14 '23 Sale 37.03 6,467 239,473 25,375 Jun 16 05:42 PM Kronenfeld Mark A. Director Jun 08 '23 Option Exercise 29.90 15,000 448,500 32,897 Jun 12 04:16 PM Kronenfeld Mark A. Director Jun 08 '23 Sale 37.04 15,000 555,600 17,897 Jun 12 04:16 PM STACK DAVID M CEO and Chairman Jun 07 '23 Sale 37.87 5,326 201,669 153,781 Jun 07 09:33 PM WINSTON ROY Chief Medical Officer Jun 07 '23 Sale 37.87 1,857 70,315 41,356 Jun 07 09:36 PM Reinhart Charles A. III Chief Financial Officer Jun 07 '23 Sale 37.87 1,371 51,913 33,626 Jun 07 09:29 PM Williams Kristen Marie Chief Administrative Officer Jun 07 '23 Sale 37.87 1,357 51,383 20,892 Jun 07 09:34 PM Ellis Ronald J. Jr. Chief Strategy Officer Jun 07 '23 Sale 37.87 1,162 43,999 30,909 Jun 07 09:20 PM REINHARDT MAX President, Rest of World Jun 07 '23 Sale 37.87 1,099 41,614 29,225 Jun 07 09:28 PM McLoughlin Dennis Chief Customer Officer Jun 07 '23 Sale 37.87 1,057 40,023 38,115 Jun 07 09:24 PM GAUGLER DARYL Chief Operating Officer Jun 07 '23 Sale 37.87 1,047 39,645 21,539 Jun 07 09:22 PM Riker Lauren Bullaro Senior Vice President, Finance Jun 07 '23 Sale 37.87 616 23,325 19,053 Jun 07 09:31 PM SLONIN JONATHAN Chief Clinical Officer Jun 07 '23 Sale 37.87 490 18,554 36,323 Jun 07 09:32 PM STACK DAVID M CEO and Chairman Jun 06 '23 Sale 38.99 5,058 197,216 159,107 Jun 07 09:33 PM MOLLOY ANTHONY Chief Lgl & Compliance Officer Jun 06 '23 Sale 38.55 4,521 174,285 12,877 Jun 07 09:26 PM WINSTON ROY Chief Medical Officer Jun 06 '23 Sale 38.99 1,779 69,365 43,213 Jun 07 09:36 PM Williams Kristen Marie Chief Administrative Officer Jun 06 '23 Sale 38.99 1,301 50,727 22,249 Jun 07 09:34 PM Reinhart Charles A. III Chief Financial Officer Jun 06 '23 Sale 38.99 1,236 48,193 34,997 Jun 07 09:29 PM Ellis Ronald J. Jr. Chief Strategy Officer Jun 06 '23 Sale 38.99 1,114 43,436 32,071 Jun 07 09:20 PM REINHARDT MAX President, Rest of World Jun 06 '23 Sale 38.99 1,054 41,097 30,324 Jun 07 09:28 PM McLoughlin Dennis Chief Customer Officer Jun 06 '23 Sale 38.99 1,014 39,537 39,172 Jun 07 09:24 PM GAUGLER DARYL Chief Operating Officer Jun 06 '23 Sale 38.99 1,005 39,186 22,586 Jun 07 09:22 PM Riker Lauren Bullaro Senior Vice President, Finance Jun 06 '23 Sale 38.99 591 23,044 19,669 Jun 07 09:31 PM SLONIN JONATHAN Chief Clinical Officer Jun 06 '23 Sale 38.99 471 18,365 36,813 Jun 07 09:32 PM MOLLOY ANTHONY Chief Lgl & Compliance Officer Jun 05 '23 Sale 38.28 2,267 86,774 17,398 Jun 07 09:26 PM GAUGLER DARYL Chief Operating Officer Jun 05 '23 Sale 38.74 1,000 38,740 23,591 Jun 07 09:22 PM Brege Laura Director Jun 05 '23 Sale 38.74 600 23,244 9,547 Jun 07 09:18 PM HASTINGS PAUL J Director Jun 05 '23 Sale 38.34 580 22,237 6,599 Jun 07 09:23 PM GAUGLER DARYL Chief Operating Officer May 31 '23 Option Exercise 34.00 2,500 85,000 26,894 Jun 02 06:28 PM GAUGLER DARYL Chief Operating Officer May 31 '23 Sale 39.08 2,500 97,700 24,591 Jun 02 06:28 PM HASTINGS PAUL J Director May 15 '23 Option Exercise 29.90 7,000 209,300 14,179 May 17 04:07 PM HASTINGS PAUL J Director May 15 '23 Sale 41.85 7,000 292,950 7,179 May 17 04:07 PM PACE GARY W Director May 11 '23 Option Exercise 29.90 7,000 209,300 144,690 May 15 06:53 PM PACE GARY W Director May 11 '23 Sale 41.78 5,015 209,527 139,675 May 15 06:53 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
